CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tenti, P.
Right arrow Articles by Ranzani, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tenti, P.
Right arrow Articles by Ranzani, G. N.
Cancer Epidemiology Biomarkers & Prevention Vol. 9, 435-438, April 2000
© 2000 American Association for Cancer Research

p53 Codon 72 Polymorphism Does Not Affect the Risk of Cervical Cancer in Patients from Northern Italy1

P. Tenti2, N. Vesentini, M. Rondo Spaudo, R. Zappatore, P. Migliora, L. Carnevali and G. N. Ranzani

Department of Human and Hereditary Pathology, Anatomic Pathology Section, University of Pavia and Instituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo [P. T., N. V., R. Z., P. M., L. C.], and Department of Genetics and Microbiology, University of Pavia, [M. R. S., G. N. R.], 27100 Pavia, Italy

A case-control study was performed to investigate the risk of cervical cancer associated with p53 polymorphism at codon 72, encoding either arginine or proline. It has been recently suggested that the arginine isoform increases the susceptibility to invasive cervical cancer; however, data remain controversial. The polymorphism was examined by both allele-specific PCR and RFLP analysis in 101 patients with primary cervical cancer and in 140 healthy women of the same age and from the same geographical area. The distribution of p53 genotypes in cervical cancer patients and in controls was not significantly different (P = 0.445), and homozygosity for arginine at residue 72 was not associated with an increased risk for cervical cancer (odds ratio, 0.81; 95% confidence interval, 0.47–1.42; P = 0.52). Similarly, different genotype distribution and increased risk were not observed when patients versus controls were analyzed according to human papillomavirus status and cancer histotype. Therefore, no evidence of association between homozygosity for p53 arginine and cervical cancer was found in our population sample.




This article has been cited by other articles:


Home page
ChestHome page
N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das
Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India
Chest, December 1, 2005; 128(6): 3999 - 4007.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu
An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology
Cancer Res., March 15, 2004; 64(6): 2251 - 2257.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Koushik, R. W. Platt, and E. L. Franco
p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z.-W. Zhang, N. J. Laurence, A. Hollowood, P. Newcomb, M. Moorghen, J. Gupta, R. Feakins, M. J. G. Farthing, D. Alderson, and J. Holly
Prognostic Value of TP53 Codon 72 Polymorphism in Advanced Gastric Adenocarcinoma
Clin. Cancer Res., January 1, 2004; 10(1): 131 - 135.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z.-W. Zhang, P. Newcomb, A. Hollowood, R. Feakins, M. Moorghen, A. Storey, M. J. G. Farthing, D. Alderson, and J. Holly
Age-associated Increase of Codon 72 Arginine p53 Frequency in Gastric Cardia and Non-Cardia Adenocarcinoma
Clin. Cancer Res., June 1, 2003; 9(6): 2151 - 2156.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A-M Martin, P A Kanetsky, B Amirimani, T A Colligon, G Athanasiadis, H A Shih, M R Gerrero, K Calzone, T R Rebbeck, and B L Weber
Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
J. Med. Genet., April 1, 2003; 40(4): e34 - 34.
[Full Text] [PDF]


Home page
Cancer Res.Home page
G. Liu, D. P. Miller, W. Zhou, S. W. Thurston, R. Fan, L.-L. Xu, T. J. Lynch, J. C. Wain, L. Su, and D. C. Christiani
Differential Association of the Codon 72 p53 and GSTM1 Polymorphisms on Histological Subtype of Non-Small Cell Lung Carcinoma
Cancer Res., December 1, 2001; 61(24): 8718 - 8722.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.